SCHEMBL1826804

SCHEMBL1826804

Cc1cc(C(=O)Nc2ccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)cc2)no1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.56
RAB9A P51151 6/20 0.56
ALDH1A1 P00352 4/20 0.56
HTT P42858 3/20 0.56
TP53 P04637 3/20 0.56
GLA P06280 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MAPT P10636 4/20 0.50
KDM4E B2RXH2 1/20 0.50
ACR P10323 1/20 0.48
IL2 P60568 1/20 0.47
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16363165 0.90 NPC1 (0.64) NPC1RAB9AALDH1A1HTTTP53
SCHEMBL5188882 0.86 NPC1 (0.71) NPC1RAB9AALDH1A1HTTTP53
SCHEMBL2785179 0.84 MAPT (0.44) NPC1RAB9AALDH1A1HTTSMN1; SMN2
SCHEMBL1826603 0.83 GFER (0.52) NPC1RAB9AALDH1A1HTTTP53
SCHEMBL1826746 0.81 RAB9A (0.73) NPC1RAB9AHTTTP53SMN1; SMN2
SCHEMBL1827469 0.81 NPC1 (0.46) NPC1RAB9AHTTTP53SMN1; SMN2
SCHEMBL1827786 0.80 RXFP2 (0.52) NPC1RAB9AHTTTP53SMN1; SMN2
SCHEMBL1827556 0.78 MAPT (0.57) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL8267173 0.78 NPC1 (0.90) NPC1RAB9AALDH1A1HTTTP53
SCHEMBL8297621 0.77 RXFP1 (0.57) NPC1RAB9AALDH1A1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319516-A1 Compounds for treating inflammatory and autoimmune disorders Synta Pharmaceuticals Corp. (US) 2011-05-11 EP disclosed
EP-2319516-A1 Compounds for treating inflammatory and autoimmune disorders Synta Pharmaceuticals Corp. (US) 2011-05-11 EP disclosed
WO-2005009954-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO disclosed
WO-2005009539-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 WO disclosed